Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of a combination of GP
chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant
therapy of locoregionally advanced nasopharyngeal carcinoma patients.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Hospital of Guangdong Medical College Cancer Hospital of Guizhou Province Hunan Cancer Hospital Wuzhou Red Cross Hospital